MONTREAL, QC -- (Marketwired) -- 02/04/14 -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer, today announced that it is continuing its efforts to re-domiciling the Company in Canada in order to capitalize on management's belief that by doing so, the Company will generate additional business expansion opportunities and gain access to financing programs available to Canadian corporations. On January 31, 2014 , the Company filed an S-4 Registration Statement wherein it is attempting to re-domicile to Canada from Colorado . "We are very pleased with the progress we have made thus far in our efforts to re-domicile the Company in Canada ," said Dr. Steve N. Slilaty , Chief Executive Officer of Sunshine Biopharma . "We are anxious to complete the re-domiciling process as we have attendant growth and financing opportunities that we believe are available to us once we have completed this action. This is important for the Company's business strategy overall and for our Adva-27a anticancer drug candidate as we advance towards clinical trials for multidrug resistant breast cancer and pancreatic cancer." About Adva-27a Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012 ). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935. Safe Harbor Forward-Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. For Additional Information Contact: Camille Sebaaly CFO Sunshine Biopharma Inc. Direct Line: 514-814-0464 firstname.lastname@example.org www.sunshinebiopharma.com Source: Sunshine Biopharma Inc.
Most Popular Stories
- Major Phone Makers Sign Anti-Phone-Theft Pledge
- College Board Offers a Sneak Peak at New SAT
- 'Beige Book' Federal Reserve Survey, April 2014: Full Text
- Salsa Legend Cheo Feliciano Killed in Car Crash
- Miss. Gov. Signs Bills to Curb Unions
- Hiring and Weekly Jobless Claims Both Edge Up
- Yellen Remarks, Market Data Give Stocks a Boost
- Chevrolet's Small SUV Coming to the U.S.
- Is This Job Too Good to Be True?
- Yahoo Struggles Despite Alibaba Boost